Targeted ovarian cancer therapy not cost-effective, study suggests

Monday, March 7, 2011 - 22:30 in Health & Medicine

An analysis conducted by cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net